Prescribing information (external link)
This is a promotional meeting organised and funded by Novartis UK Ltd., for UK healthcare professionals only.
Dermatology Connect 2026
Cosentyx® (secukinumab) is indicated for the treatment of: moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adults (alone or in combination with methotrexate [MTX]) who have responded inadequately to disease-modifying anti-rheumatic drug therapy; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy.1 Full indications can be found at the bottom of the page.
It is Dermatology Connect’s third birthday and we are back! This two-day dermatology meeting explores hot topics from the therapeutic area, along with educational sessions to improve your clinical, professional and healthcare system knowledge. Over 140 of your peers joined us in May 2025, so don't miss your opportunity to attend this event in 2026.
Reach out to your local Key Account Manager for the full agenda and registration information.
Dermatology Connect 2026
-
10:00 10:10 Hrs
Arrival & Coffee (registrar summit)10:10 10:20 Hrs
Welcome and Introduction from Chair (registrar summit)10:20 11:00 Hrs
Resilience in Dermatology (registrar summit)11:00 11:40 Hrs
Complex Cases in Dermatology (registrar summit)11:40 12:00 Hrs
Break (registrar summit)12:00 12:40 Hrs
Career Paths, Becoming a Consultant Dermatologist (registrar)12:40 13:20 Hrs
Misinformation on Social Media (registrar summit)13:20 13:30 Hrs
Summary & Close (registrar summit)13:30 14:30 Hrs
Lunch then Join Dermatology Connect14:30 14:45 Hrs
Opening Plenary: Overview of Agenda and Faculty14:45 16:30 Hrs
Hot Topic Panel Debates16:30 18:00 Hrs
Break18:00 18:30 Hrs
Networking reception18:30 18:45 Hrs
Welcome to Evening Sessions18:45 19:30 Hrs
Managing Scalp & Nail Disease in Dermatology19:30 20:15 Hrs
Listening to Our Patients: The Burden of Psoriatic Disease20:15 20:30 Hrs
Close Evening Meeting -
08:30 09:00 Hrs
Welcome to Day 209:00 12:00 Hrs
Workshop sessions (Participants can select 3 of 5 sessions)12:00 13:00 Hrs
Lunch13:00 13:15 Hrs
Introduction to Afternoon Sessions13:15 14:00 Hrs
Spotlight on HS: Aligning Treatment Goals with Real-World Needs14:00 14:45 Hrs
Pathogenesis & Beyond14:45 15:00 Hrs
Summary and Close of Event
“Derm Connect generates so much energy in the room from the interactivity between delegates and speakers and provides cutting edge ‘need to know’ information every year”
“It’s one of my favourite events”
Where is Dermatology Connect 2026?
51.528516719985, -0.12818220000001
Therapeutic Indications1
Cosentyx is indicated for the treatment of moderate to severe plaque psoriasis (PsO) in adults, children and adolescents from the age of 6 years who are candidates for systemic therapy; active psoriatic arthritis (PsA) in adult patients (alone or in combination with methotrexate [MTX]) when the response to previous disease-modifying anti-rheumatic drug therapy has been inadequate; active ankylosing spondylitis (AS) in adults who have responded inadequately to conventional therapy; active non-radiographic axial spondyloarthritis (nr-axSpA) with objective signs of inflammation as indicated by elevated C-reactive protein and/or magnetic resonance imaging evidence in adults who have responded inadequately to non-steroidal anti-inflammatory drugs; active moderate to severe hidradenitis suppurativa (HS; acne inversa) in adults with an inadequate response to conventional systemic HS therapy; active enthesitis-related arthritis (ERA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy; active juvenile psoriatic arthritis (JPsA) in patients 6 years and older (alone or in combination with MTX) whose disease has responded inadequately to, or who cannot tolerate, conventional therapy.1
AS, ankylosing spondylitis; ERA, enthesitis-related arthritis; HS, hidradenitis suppurativa; JPsA, juvenile psoriatic arthritis; MTX, methotrexate; nr-axSpA, non-radiographic axial spondyloarthritis; PsA, psoriatic arthritis; PsO, plaque psoriasis.
Reference
Cosentyx® (secukinumab) Summary of Product Characteristics.
UK | January 2026 | FA-11562108
